Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

EU Agency Rejects Sanofi SA's and Isis Pharmaceuticals Inc's Cholesterol Drug-Reuters


Friday, 14 Dec 2012 09:08am EST 

Reuters reported that European regulators have recommended against approval of Sanofi SA's and Isis Pharmaceutical Inc's drug Kynamro for treatment of a rare genetic disorder that causes unusually high cholesterol. The European Medicines Agency said it was concerned about the medicine‚Äôs safety, noting that a high proportion of patients stopped taking it within two years, mainly due to side effects such as flu-like symptoms, injection site reactions and liver toxicity. 

Company Quote

29.65
1.0 +3.49%
12:57pm EDT